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progression in such patients is the degree of proteinuria.
Objective: We aimed to retrospectively examine the protective effect of ARBs (olmesartan, losartan,
candesartan, and valsartan) on CKD patients without a history of diabetic nephropathy.
Methods: Data were retrieved from medical records of patients with a diagnosis of CKD (serum
creatinine [Cre] o3.0 mg/dL [265.2 mmol/L] and urinary protein of 0.3–3.5 g/g Cre) who were treated
with ARBs and those with diabetic nephropathy were excluded. Blood pressure, serum Cre, urinary
protein, urinary Cre, and estimated glomerular ﬁltration rate were measured before the research began
and at 1, 3, 6, 12, and 24 months after the ARB treatment was started.
Results: Forty-four patients completed the research protocol. Of these, 10 took olmesartan, 13 took
losartan, 9 took candesartan, 9 took valsartan, and 3 took telmisartan. Systolic blood pressure was
decreased in all cases. The extent of this decrease 1 month after starting ARB treatment was greater for
olmesartan than for candesartan (P o 0.05), and after 2 years, it was greater than for losartan (P o
0.05). Diastolic blood pressure decreased in all patients; this decrease was signiﬁcantly greater with
olmesartan 1 month after treatment started than with candesartan (P o 0.05). Olmesartan signiﬁcantly
decreased daily urinary protein compared with that with the other ARBs during follow-up. This
decrease 1 month after starting ARB treatment was greater for olmesartan than losartan, valsartan, and
candesartan (P o 0.01, P o 0.01, and P o 0.05, respectively), and after 2 years, this effect was still
signiﬁcant (P o 0.05, P o 0.01, and P o 0.01, respectively).
Conclusions: Olmesartan is more effective in reducing urinary protein than other ARBs, suggesting that
the renal protective effects of olmesartan may be better than those of other ARBs.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Angiotensin II receptor antagonists (ARBs) confer protection in
patients with renal insufﬁciency, delaying progression in patients
with managed hypertension. Most reported cases have been in
patients with diabetic mellitus (DM) and related kidney disease.1
The Reduction of Endpoints in Non-Insulin-Dependent Diabetes
Mellitus With the Angiotensin II Antagonist Losartan trial
reported that losartan conferred signiﬁcant renal beneﬁts inier Inc.
PhD, Renal Division, Tohma
no).
Open access under CC BY licepatients with type 2 diabetes and nephropathy.2 However,
chronic renal failure is not only DM related, but also occurs in
other conditions, such as chronic glomerular nephritis and hyper-
tensive nephrosclerosis, and the number of patients with these
conditions is equal to the number of patients with DM-related
kidney disease.3
The current research examined the protective effects of vari-
ous ARBs in patients with nondiabetic related chronic renal
failure.Patients and Methods
We used a computerized database of all patients admitted
from 2004 to June 2010 for this retrospective review. Patients
included in this review were those in whom chronic kidney
disease (CKD) had been treated with ARBs and whose diagnosisnse.
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laboratory investigations. We aimed to exclude patients with
nephritic syndrome whose urine protein was 43.5 g/g creatinine
(Cre). Internal medicine physicians specializing in diabetes exam-
ined patients with diabetic nephropathy earlier than those spe-
cializing in the kidney in our hospital. However, they did not
examine urine Cre concentrations in those patients. When
patients consult internal medicine physicians specializing in the
kidney in preparation for dialysis therapy, their CKD is already
beyond stage 4 (with a serum Cre concentration 43.0 mg/dL).
Because these Cre concentrations were outside the range of our
research, those with diabetic nephropathy were excluded. Patients
with serum Cre concentrations of 3.0 mg/dL (265.2 mmol/L) and a
urine protein of 0.3–3.5 g/g Cre when ARB treatment was started
were included in the analysis. To evaluate the effect of each ARB
and to ignore the effect of concomitant drugs, when a research
patient was taking other drugs (including a calcium antagonist,
angiotensin-converting enzyme [ACE] inhibitors [ACEIs], antipla-
telet agents, or cholesterol-reducing agents), they were not
excluded, provided that they continued to take these drugs after
ARB treatment was started and continued to take the same doses
during the research period. An arbitrary choice of ARB was not
made in any of the patients when they started treatment with an
ARB, and each patient took only 1 ARB during the research period.
The research was approved by the institutional review board, and
informed consent was waived because of the retrospective anal-
ysis design.
Blood pressure, serum Cre concentrations, urinary protein
concentrations, urinary Cre concentrations, and estimated glo-
merular ﬁltration rate (eGFR) were measured before the ARBs
were started and then at 1, 3, 6, 12, and 24 months and were
analyzed retrospectively. All urine and blood Cre concentrations
were measured using the creatinase sarcosine oxidase peroxidase
method in our hospital. This method for measuring urine and
blood Cre concentrations was used throughout this research. The
eGFR was calculated using the Japanese Kidney Society method
(male eGFR: [mL/min/1.73 m2] ¼ 194  Cre1.094  age0.287,
female eGFR: [ml/min/1.73 m2] ¼ 194  Cre1.094  age0.287
 0.739).4
Blood pressure, serum concentrations of Cre, urinary protein,
urinary creatinine, and eGFR are expressed as the mean (SD).
Changes in systolic and diastolic blood pressure and daily
urinary protein loss after starting ARB treatment did not follow
a normal distribution on a histogram. Because it was assumed
that they would closely ﬁt a log-normal distribution, these
changes were logarithmically transformed to obtain a normal
distribution. The intergroup variation from the start ofTable
Characteristics of patients who took an ARB and were nondiabetic (N ¼ 41).*
Olmes
(n ¼
Sex, M/F 3/7
Age, y 55.3 (1
Dose, mg/day 13.5 (5
SBP, mm Hg 149.0 (2
DBP, mm Hg 86.6 (8
Cre, mg/dL 1.1 (0
eGFR, mL/min 54.8 (2
K, mEq/L 4.5 (0
UP, g/g Cre 1.33 (0
Period during ARB treatment being started and diagnosed with CKD, y 15.8 (9
ARB, angiotensin II receptor antagonist; CKD, chronic kidney disease; Cre, creatin
K, potassium; SBP, systolic blood pressure; UP, urinary protein.
n Values are given as mean (SD).
y Compared with olmesartan.treatment for hypertension and urine protein concentrations
was analyzed using Dunnett’s post hoc test. Comparisons
between olmesartan and each ARB (2-group analysis; olmesar-
tan vs valsartan, olmesartan vs losartan, olmesartan vs cande-
sartan, and olmesartan vs other ARBs) for hypertension and
urine protein concentrations were analyzed using the Bonferroni
adjustment. Multigroup analysis of the 4 groups (olmesartan,
valsartan, losartan, and candesartan) for hypertension and urine
protein concentrations was performed using repeated-measures
ANOVA, assuming a 2-sided 5% signiﬁcance level and a power of
80%. Statistical analysis was performed using Microsoft Excel
2010 software.
Results
Patients’ background
The research protocol was completed by 44 patients with a
mean (SD) age of 52.8 (13.4) years; and 20 patients were men.
When ARB treatment was started, the mean (SD) systolic blood
pressure was 145.3 (22.7) mm Hg and the mean (SD) diastolic
pressure was 85.2 (13.4) mm Hg. Mean (SD) serum Cre concen-
trations were 1.1 (0.6) mg/dL, eGFR was 58.25 (25.2) mL/min/1.73
m2, serum potassium concentrations were 4.5 (0.5) mEq/L, and
urine protein concentrations were 1.24 (0.86) g/g Cre. The mean
(SD) time from the onset of CKD to starting ARB treatment was 9.5
(9.5) years (Table). A renal biopsy was performed in 8 of the 44
patients. Four patients had IgA nephropathy, 2 had membranous
nephropathy, 1 had obesity-related nephropathy, and 1 had
purpuric nephritis. In the 36 patients in whom a renal biopsy
was not performed, the diagnosis was made by the medical
history or laboratory test ﬁndings. Of these 36 patients, 34 had
a diagnosis of chronic glomerulonephritis, and 2 had a diagnosis
of hypertensive nephrosclerosis.
Of these patients, 10 took olmesartan, 13 took losartan, 9 took
candesartan, 9 took valsartan, and 3 took telmisartan. The mean
daily dose at the start of treatment was 13.5 (5.5) mg olmesartan,
28.8 (9.0) mg losartan, 6.7 (1.9) mg candesartan, 48.9 (16.6) mg
valsartan, and 33.3 (9.4) mg telmisartan. Because only 3 patients
took telmisartan and only 1 completed 2 years of follow-up, those
taking telmisartan were excluded from the research. In all
patients, the doses remained the same throughout the research
period. When ARB treatment was started, there were no signiﬁ-
cant differences in mean age, systolic and diastolic blood pres-
sure, concentrations of serum Cre, eGFR, serum potassium, and
urine protein in any of the groups of patients (Table). The only
signiﬁcant difference was the period between the onset of CKDartan
10)
Losartan
(n ¼ 13)
Candesartan
(n ¼ 9)
Valsartan
(n ¼ 9)
P
7/6 5/3 5/4 NS
1.18) 51.1 (14.2) 50.4 (14.0) 56.4 (13.1) NS
.5) 28.8 (9.0) 6.7 (1.9) 48.9 (16.6) —
3.8) 142.6 (14.9) 140.8 (19.3) 152.4 (29.6) NS
.1) 84.8 (11.1) 84.2 (12.3) 86.0 (21.1) NS
.5) 1.3 (0.4) 1.2 (0.8) 1.1 (0.7) NS
2.2) 49.1 (15.5) 70.8 (36.4) 61.4 (25.4) NS
.4) 4.3 (0.4) 4.6 (0.5) 4.7 (0.5) NS
.8) 1.17 (0.7) 1.46 (0.8) 1.20 (0.9) NS
.9) 8.1 (5.4) 8.0 (9.4) 5.3 (5.4)y o0.05y
ine; DBP, diastolic blood pressure; eGFR, estimated glomerular ﬁltration rate;
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valsartan (15.8 [9.9] years vs 5.7 [5.4] years, P o 0.05) (Table).
Serum Cre and potassium concentrations and eGFR
In all patients, there were no signiﬁcant changes in the
concentrations of serum Cre and serum potassium and eGFR.
Systolic and diastolic blood pressure
There were no signiﬁcant differences in systolic and diastolic
pressure by multigroup analysis (ANOVA) among the 4 groups.
However, we did observe a time-dependent difference in the
decrease in blood pressure between olmesartan and 2 of the ARBs
using a 2-group analysis. Systolic blood pressure was decreased in
all cases (Figure 1), but the extent of this decrease 1 month after
starting ARB treatments was greater with olmesartan than with
candesartan (P o 0.05) (Figure 2A), and after 2 years, it was
greater with olmesartan than with losartan (P o 0.05)
(Figure 2A).
Diastolic blood pressure decreased in all patients (Figure 1),
and the extent of the change was signiﬁcantly greater with
olmesartan than with losartan 1 month after the treatment
started (P o 0.05) (Figure 2B).
Daily urinary protein
There were no signiﬁcant differences in urinary protein by
multigroup analysis (ANOVA) among the 4 groups.
Urinary protein decreased with ARB treatment in all patients,
as shown by using 2-group analysis (Figure 3). Treatment with
olmesartan signiﬁcantly decreased the amount of daily urinary
protein loss compared with that with the other ARBs during
follow-up. The extent of this decrease 1 month after starting ARB
treatment was greater with olmesartan than with losartan,Figure 1. Baseline measurements of systolic and diastolic blood pressure from the st
Months indicate the time from the start of ARBs. Solid lines, systolic blood pressure; bvalsartan, and candesartan (P o 0.01, P o 0.01, and P o 0.05,
respectively), and after 2 years, this difference was still signiﬁcant
(P o 0.05, P o 0.01, and P o 0.01, respectively) (Figure 2C).
Systolic blood pressure and urinary protein signiﬁcantly
decreased with olmesartan as well as with the other ARBs,
compared with before starting ARB treatment. The amount of
urinary protein was signiﬁcantly reduced 1, 3, 6, 12, and 24
months after starting oral administration of valsartan, candesar-
tan, and losartan (P o 0.01, P o 0.05) (Figure 2). Olmesartan
signiﬁcantly reduced the amount of urinary protein at 1 month
compared with three other ARBs (valsartan, candesartan, and
losartan), and this continued over 24 months compared with that
before treatment (Po0.01) (Figure 4).
Daily urinary protein loss in the subpopulation who achieved a blood
pressure goal of 130/80 versus those who did not achieve this goal
We evaluated daily urinary protein in the subpopulation who
achieved the ARB blood pressure goal of 130/80 at 1 year after
starting ARB treatment versus those who did not achieve this blood
pressure goal. Urinary protein was decreased in the group who
achieved the blood pressure goal compared with the group who
did not (olmesartan, achievement group [n ¼ 5]: 0.92 [0.40] g/g
Cre vs the nonachievement group [n ¼ 4]: 0.51 [0.30] g/g
Cre [P o 0.01]; all ARBs, achievement group [n ¼ 27]: 0.56
[0.16] g/g Cre vs the nonachievement group [n ¼ 14]: 0.42 [0.22]
g/g Cre [P o 0.05]).Discussion
According to Japanese Evidence-based Practice Guidelines on
CKD in 2009, the number of patients with CKD in Japan exceeded
13 million, and 10 million of these patients had stage 3 disease.5
The number of patients on long-term dialysis according to ﬁgures
from the Society for Dialysis Therapy in 2008 was reported to beart of treatment. Olmesartan (A), losartan (B), valsartan (C), and candesartan (D).
roken lines, diastolic blood pressure.
Figure 2. (A) Decrease in systolic blood pressure for patients taking the 4 angiotensin II receptor antagonists (ARBs) that have been logarithmically transformed.
Olmesartan and 3 other ARBs were compared. (B) Decrease in diastolic blood pressure for patients taking the 4 ARBs that have been logarithmically transformed.
Olmesartan and 3 other ARBs were compared. (C) Decrease in daily urinary protein concentrations that have been logarithmically transformed in patients taking ARBs.
Olmesartan and 3 other ARBs were compared. Cre, creatinine. Months indicate the time from the start of ARB treatment. *P o 0.05, yP o 0.01. Solid columns, olmesartan;
hatched columns, losartan; dotted columns, valsartan; columns with horizontal lines, candesartan.
Figure 3. Baseline measurements of urinary protein from the start of treatment. Olmesartan (A), losartan (B), valsartan (C), and candesartan (D). Cre, creatinine. Months
indicate the time from the start of ARB treatment.
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Figure 4. Changes in systolic blood pressure and urinary protein. Olmesartan and 3 other angiotensin II receptor antagonists (ARBs) (valsartan, candesartan, and losartan)
were compared. The P values were calculated by comparing values after treatment with those when ARB treatment was started. Cre, creatinine; SBP, systolic blood
pressure; UP, urinary protein.*P o 0.05, yP o 0.01. Months indicate the time from the start of ARB treatment. Solid line, olmesartan; broken line, other ARBs.
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diabetic nephropathy (42.9%), chronic glomerulonephritis (25.6%),
and nephrosclerosis (9.4%).3 According to the CKD clinical practice
guidelines, it is recommended that patients with overt proteinuria
who have diabetic nephropathy, IgA nephropathy, and nephro-
sclerosis should be given an ACEI/ARB to maintain their blood
pressure at o130/80 mm Hg.6 Many of the reports that describe
the use of ARBs, which are effective in preserving renal function,
relate to patients with diabetic nephropathy.1,7 Many studies on
nondiabetic chronic renal failure patients have provided evidence
regarding the efﬁcacy of ACEIs,8,9 but few reports have discussed
the use of ARBs.10–12
In the current research, we treated nondiabetic patients with
various ARBs and evaluated changes in their blood pressure,
urinary protein, and renal function. In our patients, blood pres-
sure and urinary protein were reduced by ARB treatment. A
reduction in urinary protein suggests a protective effect on kidney
function13 without causing any side effects. In particular, olme-
sartan decreased the amount of loss of urinary protein and
decreased blood pressure more rapidly than the other ARBs. Even
though there were no signiﬁcant differences in multigroup
analysis among the groups (olmesartan, valsartan, losartan, and
candesartan), in 2-group analysis (olmesartan vs valsartan, olme-
sartan vs losartan, olmesartan vs candesartan, and olmesartan vs
other ARBs), there was a signiﬁcant difference within 1 month of
starting treatment.
The reason for this difference between olmesartan and the
other ARBs is unclear. The reason why urinary protein loss with
olmesartan was greater than that with the other ARBs may be
because the decrease in blood pressure with olmesartan
occurred earlier than that with the other ARBs. There are some
reports that olmesartan provides better antihypertensive efﬁcacy
than other ARBs.14,15 In our analysis, we found that urinary
protein decreased more in the achievement group (olmesartan
and the other ARBs; blood pressure, 130/80 mm Hg) than that in
the nonachievement group. This ﬁnding indicates that this
antihypertensive effect promotes a decrease in urinary protein.
It has also been reported that the antihypertensive action and
duration of olmesartan may be greater compared with thosewith the other ARBs.16,17 When comparing olmesartan and the
other ARBs, the degree of decrease in urinary protein 2 years
after starting ARB treatment was greater than the degree of
decrease in blood pressure. Therefore, there may be other
reasons why olmesartan reduced urinary protein more than the
other ARBs.
Olmesartan has a double-chained domain consisting of carboxyl
and hydroxyl groups, which can strongly combine with the ARB
type 1 (AT1) and block the action of angiotensin II. In addition, the
receptor itself depends on inverse agonist activity inhibiting
mechanical stress caused by the stretching of cells, which is to be
expected in organs such as the heart and kidney.18,19
It has been reported that there is an ACE/angiotensin II/AT1
receptor axis, as well as an ACE2/angiotensin 1-7/Mas receptor
axis, and the balance of both axes leads to a protective effect on
organs, such as the heart and kidney.20 As a consequence of AT1
blockade, ARBs increase angiotensin II levels severalfold above
baseline by compensatory feedback.21 It has also been shown that
olmesartan reduces angiotensin II levels, contrary to expectations,
and does not produce aldosterone breakthrough.22 Therefore, it
was considered that a decrease in angiotensin II does not lead to
aldosterone breakthrough.
In Wistar Kyoto rats, olmesartan interacts with ACE2 and
increases Ang1-7. Ang 1-7 interacts with the Mas receptor, which
has a cardiac and renal protective effect.23,24
ARBs, except for olmesartan, have been found to activate
ACE2; however, they have to be at much higher doses than
olmesartan to activate ACE2.25Conclusions
Our results suggest that olmesartan decreases blood pressure
and protein loss in patients with nondiabetic chronic renal failure
more than other ARBs, and this effect may prolong renal function.
Additionally, it is possible that the renal protective activity of
olmesartan is due to not only an antihypertensive effect but also
to other factors. This analysis was retrospective, not a prospective,
randomized trial, and the number of patients was too small to
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concomitant medications was a limitation of this research.
Because this was a retrospective evaluation comparing different
groups, the medications may have been different and may have
enhanced or reduced the response in 1 group versus another.
There were no differences among the 4 groups in multigroup
analysis (ANOVA). Therefore, another limitation of this analysis is
that it was underpowered. The prescription of ARBs was not
inﬂuenced by the evaluation team. This is also a limitation in that
the prescribing physicians could have been biased in their
determination of which ARB to use for a given patient.
Therefore, to determine whether olmesartan has a renal
protective effect other than an antihypertensive protective effect,
a prospective, randomized, large-scale study is necessary.Acknowledgments
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